LLY

1,056.46

+2.42%↑

JNJ

243.54

+0.5%↑

ABBV

231.21

+3.45%↑

NVS

162.41

+1%↑

MRK

121.65

+1.48%↑

LLY

1,056.46

+2.42%↑

JNJ

243.54

+0.5%↑

ABBV

231.21

+3.45%↑

NVS

162.41

+1%↑

MRK

121.65

+1.48%↑

LLY

1,056.46

+2.42%↑

JNJ

243.54

+0.5%↑

ABBV

231.21

+3.45%↑

NVS

162.41

+1%↑

MRK

121.65

+1.48%↑

LLY

1,056.46

+2.42%↑

JNJ

243.54

+0.5%↑

ABBV

231.21

+3.45%↑

NVS

162.41

+1%↑

MRK

121.65

+1.48%↑

LLY

1,056.46

+2.42%↑

JNJ

243.54

+0.5%↑

ABBV

231.21

+3.45%↑

NVS

162.41

+1%↑

MRK

121.65

+1.48%↑

Search

CareDx Inc

Open

SectorGezondheidszorg

20.05 2.77

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.77

Max

19.89

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

15.773

121.746

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-10.85% downside

Dividenden

By Dow Jones

Volgende Winsten

24 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

288M

1.1B

Vorige openingsprijs

17.28

Vorige sluitingsprijs

20.05

Nieuwssentiment

By Acuity

11%

89%

9 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 feb 2026, 23:57 UTC

Populaire aandelen

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12 feb 2026, 23:35 UTC

Winsten
Belangrijke Marktbewegers

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12 feb 2026, 23:28 UTC

Winsten

Applied Materials Profit Rises on Soaring AI Demand -- Update

12 feb 2026, 21:47 UTC

Winsten

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13 feb 2026, 00:00 UTC

Marktinformatie

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12 feb 2026, 23:47 UTC

Marktinformatie

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12 feb 2026, 23:38 UTC

Marktinformatie

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12 feb 2026, 23:33 UTC

Winsten

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12 feb 2026, 23:09 UTC

Marktinformatie

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12 feb 2026, 22:55 UTC

Winsten
Populaire aandelen

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12 feb 2026, 22:46 UTC

Marktinformatie

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12 feb 2026, 22:23 UTC

Winsten

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12 feb 2026, 22:15 UTC

Winsten

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12 feb 2026, 22:15 UTC

Winsten

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12 feb 2026, 22:15 UTC

Winsten

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12 feb 2026, 22:15 UTC

Winsten

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12 feb 2026, 22:00 UTC

Winsten

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 feb 2026, 22:00 UTC

Winsten

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12 feb 2026, 22:00 UTC

Winsten

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12 feb 2026, 22:00 UTC

Winsten

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12 feb 2026, 22:00 UTC

Winsten

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 feb 2026, 22:00 UTC

Winsten

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12 feb 2026, 21:57 UTC

Winsten

XP 4Q Rev BRL4.95B >XP

12 feb 2026, 21:52 UTC

Winsten

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb 2026, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

12 feb 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

12 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 feb 2026, 21:47 UTC

Winsten

Morningstar 4Q Rev $641M >MORN

12 feb 2026, 21:39 UTC

Winsten

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb 2026, 21:38 UTC

Winsten

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

-10.85% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD  -10.85%

Hoogste 18 USD

Laagste 18 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

3 ratings

0

Buy

3

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

9 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat